Clinical Trials

Multiple Myeloma

NCT06911502 2026-05-20

A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)

400 enrolled

Lymphoma, Follicular

NCT04661007 2026-05-18

J-MIND

72 enrolled

Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT05623020 2026-05-14

MagnetisMM-6

1,116 enrolled

Multiple Myeloma

NCT03934684 2026-05-11

Study to Evaluate Safety Tolerability & Efficacy of Kyprolis (Carfilzomib) in Relapsed or Refractory Multiple Myeloma

Phase 4 Completed

101 enrolled 14 charts

Multiple Myeloma

NCT05669989 2026-05-11

International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab

70 enrolled

Multiple Myeloma

NCT03901963 2026-05-08

AURIGA

200 enrolled 12 charts

Phase 1 Active not recruiting

Multiple Myeloma

NCT04722146 2026-05-08

MajesTEC-2

140 enrolled

Multiple Myeloma

NCT04923893 2026-05-08

CARTITUDE-5

743 enrolled

Phase 1 Active not recruiting

Multiple Myeloma

NCT05050097 2026-05-08

MonumenTAL-2

166 enrolled

Multiple Myeloma

NCT05438043 2026-05-08

A Study of Daratumumab

500 enrolled

Multiple Myeloma

NCT05552222 2026-05-08

MajesTEC-7

1,590 enrolled

Multiple Myeloma

NCT06577025 2026-05-08

aMMbition

43 enrolled

Multiple Myeloma

NCT06768489 2026-05-08

A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide or in Combination With Pomalidomide for Multiple Myeloma

Phase 1 Recruiting

140 enrolled

Multiple Myeloma

NCT04126200 2026-05-06

DREAMM 5

208 enrolled 5 charts

LymphoidOther hematologic neoplasm

Multiple Myeloma

NCT05283720 2026-05-06

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma

Phase 2 Recruiting

496 enrolled

Leukemia, Hairy Cell, Lymphoma, Non-Hodgkin, Neoplasms, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT06149286 2026-05-06

OLYMPIA-5

470 enrolled

Lymphoma, Follicular, Recurrence, Lymphoma, B-Cell, Marginal Zone

NCT06191744 2026-05-06

EPCORE™FL-2

1,095 enrolled

Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Neoplasms

NCT04542824 2026-05-05

EPCORE™ NHL-3

LymphoidOther hematologic neoplasm

78 enrolled

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone

NCT04623541 2026-05-05

EPCORE™ CLL-1

LymphoidOther hematologic neoplasm

195 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04663347 2026-05-05

EPCORE™ NHL-2

543 enrolled

Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse

NCT04712097 2026-05-05

Celestimo

478 enrolled

Lymphoma, Follicular, Recurrence

NCT05429268 2026-05-05

firmMIND

82 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT05660967 2026-05-05

EPCORE DLBCL-3

111 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT02343042 2026-05-04

STOMP

300 enrolled

Multiple Myeloma, Recurrence

NCT03173092 2026-05-04

A Study of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) for the Treatment of Participants With Multiple Myeloma (MM)

Phase 4 Terminated

141 enrolled

Multiple Myeloma

NCT03319667 2026-05-04

IMROZ

475 enrolled 1 FDA

Multiple Myeloma

NCT05583617 2026-05-04

PLYCOM

Phase 1/2 Recruiting

200 enrolled

Multiple Myeloma

NCT06084936 2026-05-04

GLOBRYTE

182 enrolled

Phase 2 Not yet recruiting

Lymphoma

NCT07560449 2026-05-01

QLS4131 Combination Therapy in Malignant Plasma Cell Neoplasms

162 enrolled

Phase 3 Not yet recruiting

Malignant Plasma Cell Neoplasms

NCT07562022 2026-05-01

A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma

93 enrolled

Lymphoma, Follicular

NCT05090566 2026-04-24

MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma

Phase 2 Terminated

46 enrolled 15 charts

Multiple Myeloma

NCT06679101 2026-04-22

DREAMM-10

520 enrolled

Multiple Myeloma

NCT04224493 2026-04-20

SYMPHONY-1

555 enrolled

Lymphoma, Follicular

NCT04404283 2026-04-20

ECHELON-3

239 enrolled 1 FDA

Lymphoma, Large B-Cell, Diffuse

NCT05888493 2026-04-17

LEDA

109 enrolled

Lymphoma, Follicular, Recurrence

NCT05317416 2026-04-16

MagnetisMM-7

854 enrolled

Hematologic Diseases, Multiple Myeloma

NCT02719613 2026-04-15

Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab

Phase 2 Completed

67 enrolled

Multiple Myeloma

NCT04133636 2026-04-13

CARTITUDE-2

210 enrolled

Multiple Myeloma

NCT03984097 2026-04-09

A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM)

Phase 1 Completed

50 enrolled

Multiple Myeloma, Neoplasms, Plasma Cell

NCT03652064 2026-04-08

A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy

395 enrolled 11 charts 1 FDA

Multiple Myeloma

NCT06508658 2026-04-08

EPCORE DLBCL-4

379 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT04824092 2026-04-01

frontMIND

899 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT04903197 2026-04-01

Study of VAY736 as Single Agent and in Combination With Select Antineoplastic Agents in Patients With Non-Hodgkin Lymphoma

Phase 1 Terminated

18 enrolled

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT04246086 2026-03-19

A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab + Lenalidomide (+Len), and the Safety, Tolerability, and Pharmacokinetics of SC Versus IV Mosunetuzumab + Len in Participants With Follicular Lymphoma

237 enrolled

Lymphoma, Follicular

NCT06313996 2026-03-18

A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma

Phase 3 Withdrawn

Lymphoma, Follicular, Recurrence

NCT01615029 2026-03-16

Daratumumab in Combination With Lenalidomide and Dexamethasone in Relapsed and Relapsed-refractory Multiple Myeloma

Phase 1/2 Completed

45 enrolled 14 charts

Multiple Myeloma, Recurrence

NCT05827016 2026-03-13

A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma

1,216 enrolled

Multiple Myeloma

NCT06045806 2026-03-05

KarMMa-9

79 enrolled